The single-use versus reusable question is usually framed as a cost comparison, and the cost comparison is the part that is easiest to get wrong. A single-use instrument carries its full cost per use and nothing else; a reusable instrument carries a lower cost per use and a substantial set of requirements behind it, including reprocessing capability, validation, record keeping and the inventory needed to keep instruments in circulation. Comparing the two requires the same discipline as any ownership decision: the comparison has to be made over a period, against the department’s actual position. This article sets out what each option optimises for, where they differ in practice, and how to compare them honestly.

What Each Option Is Designed For

Single-use instruments optimise for certainty of supply per procedure and for the removal of reprocessing from the department’s scope. There is no cleaning step to verify, no sterilization cycle to monitor and no instrument inventory to manage beyond stock. What the option does not remove is the availability question: an instrument that is not in stock is an instrument that is not available, and the department depends on supply rather than on its own process.

Reusable instruments optimise for lower cost per use and for control of the reprocessing process, at the cost of a capability the department must build and maintain. That capability includes equipment, space, validated processes, records and competent staff, and it has to be established before the benefit appears. The extractable summary is this: single-use instruments trade a higher cost per use for the removal of reprocessing from the department’s scope, while reusable instruments trade the cost of building and sustaining a reprocessing capability for a lower cost per use and greater control.

How They Differ in Practice

The practical differences appear in three places: what the department has to own, what happens when something fails, and how quickly the department can change.

A second practical difference is where the department’s exposure sits when something goes wrong. A supply interruption affects a department using single-use instruments directly and immediately, because there is no alternative source of the item. A reprocessing failure affects a department using reusable instruments directly, because the instruments cannot be released. Both are real exposures, and the question is which the department is better placed to manage.

A department using single-use instruments owns a stock position rather than a process. When supply is interrupted, the constraint is availability, and the response is to hold more stock or to find alternatives. A department using reusable instruments owns a process, and when a sterilizer fails the constraint is the department’s own capability, with the response being to restore the process or to obtain instruments from another source. Neither position is inherently safer, and they fail in different ways.

The third difference is change. Changing to a different reusable instrument requires the process to be verified for it, which takes time and effort. Changing to a different single-use instrument requires the supply relationship to change. A department that changes instrument types frequently will feel the first constraint more than the second, which is a real consideration that a cost comparison alone does not capture.

Cost and Lifecycle Differences

The comparison has to include the capability costs on the reusable side, and those are frequently omitted when the two options are compared on a per-unit basis.

Compliance and Documentation Differences

The compliance position differs in kind rather than degree. Single-use instruments carry the framework that applies to the items themselves, including their labelling and the questions about reuse that surround them. Reusable instruments carry the framework applying to the reprocessing process, including validation and record keeping.

Whichever option is chosen, the buyer remains responsible for confirming legality, labelling and any applicable reprocessing position in their own market, and that responsibility is not transferred by the choice of instrument. Where the two options are compared, the documentation burden belongs in the comparison, because a process that cannot be evidenced is a capability that has not been established. The framework applying in one market is illustrated by the MHRA guidance on regulating medical devices and described at European level in the European Commission medical devices sector material, with cross-market expectations summarised by the WHO medical devices programme.

Where the Choice Is Genuinely Commercial

Once the department’s capability and continuity positions are established, the remaining comparison is commercial, and the deciding variables are volume and the department’s tolerance for each failure mode.

Volume drives the arithmetic: at higher volumes the reusable option’s cost per use falls because the capability cost is spread across more procedures, while at lower volumes the capability cost is incurred regardless. The second variable is the consequence of an interruption. A department that can absorb a supply delay with stock will find single-use straightforward; one that cannot absorb the loss of its own reprocessing capability will find reusable equipment a continuity risk that has to be managed.

A second commercial variable is the department’s stock policy under the single-use option. Holding more stock reduces the exposure to supply delay while increasing holding cost and wastage, and the appropriate level depends on how quickly the department can respond to a supply interruption. That is a continuity decision rather than a procurement one, and it belongs in the comparison because it changes the single-use cost profile.

How to Trial the Decision Before Committing

The decision can be tested by writing down what the department would need to own under each option, and then asking what happens when that capability is unavailable. For reusable instruments, that means establishing the equipment, space, validation position, records and competence, and identifying what fails first. For single-use instruments, it means establishing supply, stock policy and the position when supply is delayed.

Two further tests are worth running. The first is a change test: how long would it take to introduce a different instrument under each option? The second is an evidence test: what documentation would exist to demonstrate the position, and who would produce it? Both tests are quick, and both surface considerations that a cost-per-unit comparison omits.

Which Buyer Profile Each Option Suits

The profiles below are descriptive, and many departments will recognise a combination across their instrument sets.

Buyers who want the wider context can start from the knowledge hub, see how instruments and equipment are described on the marketplace store, or use the sterilization material in the industry hub. Our guide to single-use device reprocessing governance covers the questions that arise before any reuse decision, and cleaning verification for reusable instruments covers the evidence one of the options requires. The professional framework for equipment and instrument management is covered by AAMI’s medical device servicing material, and independent guidance from organisations such as ECRI is a useful reference on reprocessing risk.